CL2023003357A1 - Régimen de dosis para terapia combinada dirigida a dll3 y pd-1 - Google Patents

Régimen de dosis para terapia combinada dirigida a dll3 y pd-1

Info

Publication number
CL2023003357A1
CL2023003357A1 CL2023003357A CL2023003357A CL2023003357A1 CL 2023003357 A1 CL2023003357 A1 CL 2023003357A1 CL 2023003357 A CL2023003357 A CL 2023003357A CL 2023003357 A CL2023003357 A CL 2023003357A CL 2023003357 A1 CL2023003357 A1 CL 2023003357A1
Authority
CL
Chile
Prior art keywords
combination therapy
dosage regimen
dll3
therapy targeting
targeting dll3
Prior art date
Application number
CL2023003357A
Other languages
English (en)
Spanish (es)
Inventor
Hashemi Sadraei Nooshin
SHETTY Aditya
MINOCHA Mukul
Damiette SMIT Marie-Ann
Wong Hansen
Roychoudhury Siddhartha
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2023003357A1 publication Critical patent/CL2023003357A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2023003357A 2021-05-10 2023-11-10 Régimen de dosis para terapia combinada dirigida a dll3 y pd-1 CL2023003357A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163186569P 2021-05-10 2021-05-10

Publications (1)

Publication Number Publication Date
CL2023003357A1 true CL2023003357A1 (es) 2024-06-07

Family

ID=84029376

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003357A CL2023003357A1 (es) 2021-05-10 2023-11-10 Régimen de dosis para terapia combinada dirigida a dll3 y pd-1

Country Status (12)

Country Link
US (1) US20240317856A1 (enExample)
EP (1) EP4337252A4 (enExample)
JP (1) JP2024518947A (enExample)
KR (1) KR20240006585A (enExample)
CN (1) CN117377488A (enExample)
AU (1) AU2022273509A1 (enExample)
CA (1) CA3217141A1 (enExample)
CL (1) CL2023003357A1 (enExample)
IL (1) IL307646A (enExample)
MX (1) MX2023013227A (enExample)
TW (1) TW202309092A (enExample)
WO (1) WO2022240688A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP4482586A1 (en) * 2022-02-23 2025-01-01 Amgen Inc. Cancer treatment targeting dll3
KR20250116698A (ko) * 2022-12-08 2025-08-01 암젠 인크 Dll3-발현 암의 치료 방법
CN121620371A (zh) * 2023-05-19 2026-03-06 勃林格殷格翰国际公司 T细胞衔接蛋白在治疗癌症中的用途
CN120168667B (zh) * 2025-03-18 2026-04-14 中国科学院近代物理研究所 一种多肽在制备dll3过度表达的肿瘤的特异性靶向分子探针中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
EP3337517A4 (en) * 2015-08-20 2019-04-17 Abbvie Stemcentrx LLC ANTI-DLL3 ANTIBODY AGGREGATE CONJUGATES AND METHOD OF USE
CR20200539A (es) * 2018-04-10 2021-07-01 Kite Pharma Inc Receptores quiméricos de dll3 y métodos para su uso
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白

Also Published As

Publication number Publication date
CN117377488A (zh) 2024-01-09
US20240317856A1 (en) 2024-09-26
MX2023013227A (es) 2024-01-29
IL307646A (en) 2023-12-01
EP4337252A1 (en) 2024-03-20
CA3217141A1 (en) 2022-11-17
AU2022273509A1 (en) 2023-10-19
KR20240006585A (ko) 2024-01-15
WO2022240688A1 (en) 2022-11-17
TW202309092A (zh) 2023-03-01
EP4337252A4 (en) 2025-04-23
JP2024518947A (ja) 2024-05-08

Similar Documents

Publication Publication Date Title
MX2023013227A (es) Regimen de dosis para terapia combinada dirigida a dll3 y pd-1.
MX2022005596A (es) Regimen de dosificacion para agentes anti-dll3.
CL2020002945A1 (es) Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t
CL2024002529A1 (es) Tratamiento del cáncer dirigido a dll3
CO2019013020A2 (es) Anticuerpo anti-cdh6 y conjugado farmaco-anticuerpo anticdh6
DOP2023000107A (es) Compuesto de heteroarilcarboxamida
MX2017013270A (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
MX2021001083A (es) Regimen posologico para anticuerpos biespecificos contra bcma-cd3.
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
MX388093B (es) Dosis y regimen para inhibidores de la interaccion hdm2-p53.
CL2020000271A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr y un inhibidor de quinasa dependiente de ciclina.
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
CO2023009635A2 (es) Conjugado de anticuerpo anti-dll3-fármaco
CO2021014370A2 (es) Regímenes de dosificación para anticuerpos anti-vrs y composiciones que los incluyen
MX2024003918A (es) Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer.
ECSP23076276A (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
MX2022005628A (es) Regimen de dosificacion para agentes anti-bcma.
MX2025001181A (es) Regimenes de dosificacion que comprenden un inhibidor kat6 para el tratamiento de cancer
MX2024012368A (es) Terapia combinada para el tratamiento del cancer
PE20151751A1 (es) Metodos de tratamiento de la deficiencia de hierro con pirofosfato ferrico soluble
BR112022018161A2 (pt) Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer
MX2022003610A (es) Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
JOP20250015A1 (ar) تركيبة صيدلانية للأجسام المضادة ضد cd20 واستخداماتها
MX2024010392A (es) Remibrutinib para el uso en el tratamiento de hidradenitis supurativa.
AR124527A1 (es) Métodos de tratamiento de tumores